The incidence of ovarian cancer among Singapore women has been rising over the past four decades, with the local incidence rate falling between those of Western Europe and the USA.
INTRODUCTION
The incidence of ovarian cancer among Singapore women has been rising over the past four decades, with the local incidence rate falling between those of Western Europe and the USA. (1) In Singapore, ovarian cancer accounts for 5.7% of all female cancers and ranks as the fifth most common cancer among Singapore women (breast cancer ranks first, followed by colorectal, lung and uterine cancer). (2) Most ovarian cancers are epithelial in origin. The presenting symptoms are often ill-defined in the early stages. Thus, the majority are diagnosed at an advanced stage, resulting in a poor overall five-year survival rate of less than 45%.
It has been shown that women with ovarian cancer have a better prognosis if the full surgical staging procedure is carried out initially by a trained gynaecological oncologist. (3) Therefore, preoperative knowledge of the nature of the adnexal mass is necessary so that optimal surgery can be planned at the time of initial treatment. The challenge for general gynaecologists has been how to differentiate a benign adnexal mass from a malignant one so that an appropriate referral can be made preoperatively.
The risk of malignancy index (RMI) has been shown to be a triage tool with the potential to reduce the workload in a busy gynaecological unit.
The aim of this study was to determine the value of the RMI as a triage tool by evaluating the four indices (RMI 1, RMI 2, RMI 3, and RMI 4) and comparing their specificity and sensitivity in discriminating a benign ovarian mass from a malignant one.
METHODS
This was a five-year retrospective study conducted from November 2004 to October 2009 in female patients who were admitted to our hospital for surgery due to ovarian masses.
Only patients who had both cancer antigen (CA)-125 tests and ultrasonography performed in the same hospital were included in the study. The local research ethics committee had deemed that no ethics approval was required, as this was a retrospective review of patients' case notes.
RMI was calculated by multiplying the results of ultrasonography score (U) by menopausal status (M) and blood levels of ovarian CA-125 (measured in U/mL). All RMI used the same basic formula but differed in the scores that were assigned to U and M. RMI 4 included tumour size (S) measured by ultrasonography ( Based on the data obtained, the RMI 1, 2, 3 and 4 scores were calculated. An RMI value ≥ 200 was considered to be a high risk of malignancy and a value < 200 was considered to be a low risk of malignancy. (4) (5) (6) The data were analysed using the Statistical Package for the Social Sciences version 17, and Mann-Whitney U test was used to compare the individual RMI between the benign and malignant cases. A p-value < 0.0.5 was considered to be statistically significant.
RESULTS
The clinical records of 480 patients were reviewed. Out of these, 228 (47.5%) patients who had both CA-125 tests and ultrasonography performed in the same hospital were included based on the selection criteria. Out of 228 patients, 17 (7.5%) had malignant disease and 211 (92.5%) had benign pathology. The distribution of diagnoses and stages of disease in the cohort is shown in Table II .
Our study showed no statistical difference in RMI 1, 2, 3 and 4 scores between the benign and malignant cases (Table III, Fig 1) . The distribution of benign and malignant cases by age, menopausal status, ultrasonography score and tumour size is shown in Table IV . Individual variables analysed showed significant differences in median CA-125 and tumour size (p = 0.044 and p < 0.0005, respectively) between the benign and malignant cases (Table IV) . The performance of RMI 1, 2, 3 and 4 at different cut-off levels showed improved sensitivity but with a corresponding loss in specificity (Table V) .
DISCUSSION
RMI is a straightforward algorithm that is simple to apply in clinical practice. It uses inexpensive tests that are commonly available and easily reproducible. The risk of malignancy index (RMI 1) was originally developed by Jacobs et al in 1990.
Subsequently, Tingulstad et al developed RMI 2 in 1996, (5) and modified it to derive RMI 3 in 1999. (6) The difference among 
It has been shown that using a cut-off value of 200 (regardless of scoring system) for an RMI score achieves sensitivities ranging from 70% to 87%, and specificities from 89% to 97%. (4) (5) (6) (7) However, RMI uses ultrasonography imaging, which is subject to interpreter variability between and within centres, as well as variation between patient populations. Using data obtained within the same hospital, Jacobs et al reported a sensitivity and specificity of 85.4% and 96.9%, respectively, using an RMI score of 200, but a sensitivity and specificity of 95.1% and 76.5%, respectively, with an RMI score of 50. (4) Manjunath et al (9) reported a sensitivity and specificity of 73% and 91%, respectively, attributing the lower sensitivity to a higher percentage of premenopausal ovarian cancer patients compared to that of earlier studies by Jacobs et al and Davies et al. (4, 10) Besides RMI, a variety of methods for the detection of early ovarian cancer has been investigated. Human epididymis secretory protein 4 (HE4) is a recent example. Overexpressed in ovarian cancers, especially in serous epithelial tumours, this novel biomarker has been shown to have a sensitivity similar to CA-125 and a higher specificity than CA-125 in distinguishing between patients with ovarian cancer and those with benign gynaecologic conditions. (11) Recognising that HE4 was a promising of 84% and specificity of 98.5% when two of the three tests were positive. (13) Given the myriad of choices, further validation is needed before these screening tools can be added to clinical practice.
Our study was confounded by the large number of endometriotic cysts that presented as complex ovarian cysts with both high CA-125 levels and ultrasonography scores. These endometriotic cysts comprised 74.8% of benign cases and were the main limiting factor of our study. This calls into question how well RMI would perform in triaging cases of malignant ovarian cysts versus benign but complex-looking endometriotic cysts in our hospital. Other limiting factors in our study included its retrospective nature, the small sample size and possible interobserver variability among sonographers.
In conclusion, this study has shown that RMI is not a valuable tool in the triage of our Southeast Asian population.
Further prospective validation is required with regard to the standardisation of results in different patient populations and centres. 
